What is HC Wainwright's Estimate for SABS Q3 Earnings?

Key Points

• HC Wainwright lowered its Q3 2026 EPS estimate for SAB Biotherapeutics to a loss of $0.29 per share, from a previous loss estimate of $0.26.
• Despite the reduced forecast, HC Wainwright maintained its Buy rating and $10 price target. Its full-year 2026 estimate remains a loss of $1.21 per share.
• SAB Biotherapeutics recently reported a Q3 loss of $0.28 per share, matching analysts’ consensus estimate; the stock has a broader analyst consensus of “Moderate Buy” with a $12 price target.

SAB Biotherapeutics, Inc. (NASDAQ:SABS - Free Report) - Research analysts at HC Wainwright lowered their Q3 2026 earnings estimates for shares of SAB Biotherapeutics in a report released on Thursday, August 6th. HC Wainwright analyst E. Bodnar now forecasts that the company will post earnings per share of ($0.29) for the quarter, down from their prior estimate of ($0.26). HC Wainwright currently has a "Buy" rating and a $10.00 target price on the stock. The consensus estimate for SAB Biotherapeutics' current full-year earnings is ($1.21) per share. HC Wainwright also issued estimates for SAB Biotherapeutics' Q4 2026 earnings at ($0.31) EPS, FY2026 earnings at ($1.21) EPS, FY2027 earnings at ($0.60) EPS, FY2028 earnings at ($0.47) EPS, FY2029 earnings at ($0.48) EPS and FY2030 earnings at ($0.48) EPS.

Other equities research analysts also recently issued research reports about the company. Leerink Partners upped their target price on SAB Biotherapeutics from $7.00 to $12.00 and gave the stock an "outperform" rating in a research report on Monday, June 15th. Citigroup assumed coverage on SAB Biotherapeutics in a report on Friday, May 22nd. They set a "buy" rating and a $11.00 target price on the stock. Wall Street Zen raised SAB Biotherapeutics from a "strong sell" rating to a "sell" rating in a research report on Monday. Chardan Capital upped their price target on SAB Biotherapeutics from $14.00 to $16.00 and gave the stock a "buy" rating in a report on Wednesday, June 17th. Finally, Weiss Ratings downgraded shares of SAB Biotherapeutics from a "sell (d+)" rating to a "sell (e+)" rating in a research report on Thursday. Nine research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, SAB Biotherapeutics has an average rating of "Moderate Buy" and a consensus price target of $12.00.

SAB Biotherapeutics Stock Performance

NASDAQ:SABS opened at $3.90 on Monday. The business's 50-day moving average is $3.68 and its two-hundred day moving average is $3.83. The company has a debt-to-equity ratio of 0.01, a current ratio of 9.22 and a quick ratio of 9.22. SAB Biotherapeutics has a 12 month low of $1.85 and a 12 month high of $5.15. The firm has a market capitalization of $354.86 million, a PE ratio of -3.00 and a beta of 0.53.

SAB Biotherapeutics (NASDAQ:SABS - Get Free Report) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.28) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.28).

Hedge Funds Weigh In On SAB Biotherapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Dimensional Fund Advisors LP purchased a new stake in shares of SAB Biotherapeutics during the third quarter worth about $32,000. ADAR1 Capital Management LLC purchased a new position in SAB Biotherapeutics in the third quarter valued at about $30,000. Virtu Financial LLC purchased a new position in SAB Biotherapeutics in the third quarter valued at about $40,000. RA Capital Management L.P. acquired a new stake in SAB Biotherapeutics during the 3rd quarter valued at approximately $8,847,000. Finally, Vivo Capital LLC acquired a new stake in SAB Biotherapeutics during the 3rd quarter valued at approximately $22,954,000. 7.82% of the stock is owned by hedge funds and other institutional investors.

SAB Biotherapeutics News Summary

Here are the key news stories impacting SAB Biotherapeutics this week:

• Positive Sentiment: Brookline Capital Markets raised its FY2030 EPS estimate for SAB Biotherapeutics; the latest report adds to a series of upward revisions, including improved forecasts for fiscal 2027 and 2028 and a shift to projected profitability of $0.48 per share in FY2029. SABS FY2030 EPS Estimate Lifted by Brookline Capital Markets
• Positive Sentiment: Brookline also raised its Q3 and Q4 2026 EPS estimates to a loss of $0.24 per share from losses of $0.25, and improved its FY2027 estimate to a $0.95 loss from a $1.07 loss. These revisions suggest the firm expects losses to narrow faster than previously forecast. Brookline Capital Markets SAB Biotherapeutics estimates
• Neutral Sentiment: HC Wainwright reiterated its “Buy” rating and $10 price target, substantially above the recent trading level. However, its updated projections still call for losses of $1.21 per share in FY2026 and $0.60 in FY2027, compared with the current consensus FY2026 loss estimate of $1.19 per share. Analysts Offer Insights on Healthcare Companies
• Negative Sentiment: HC Wainwright lowered its Q3 and Q4 2026 EPS estimates to losses of $0.29 and $0.31, respectively, and cut its FY2026 through FY2030 forecasts. The firm now expects a $0.48 loss in both FY2029 and FY2030, indicating a slower path to profitability than Brookline projects. HC Wainwright SAB Biotherapeutics estimates

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company's proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company's lead programs are directed primarily at infectious diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source